chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Nausea; Chills; Headache -  headache as bad if not worse than my brain tumor headache except in back of head; Fatigue - still fatigued beyond belief/ Still very tired since last dose and it's been over a month; Legs so weak when ''I'' got out of bed, legs buckled; This is a spontaneous report from a contactable consumer, the patient. A 69-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 03Mar2021 at 11:30 (at the age of 69-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8730) via an unspecified route of administration in the left arm on 24Mar2021 at 11:30 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. Medical history included brain tumor, diabetes, congestive heart failure, lichen sclerosis, hypertension, high cholesterol and had unspecified allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the vaccination. Concomitant medications included metformin (MANUFACTURER UNKNOWN), mirabegron (MYRBETRIQ), amiloride (MANUFACTURER UNKNOWN), lamotrigine (MANUFACTURER UNKNOWN) and other unspecified medication; all for an unknown indication from an unknown date and unknown if ongoing. On 03Mar2021 at 14:00, the patient experienced chills, headache - headache as bad if not worse than her brain tumor, headache except in back of head, fatigue-still fatigued beyond belief, legs so weak when she got out of bed, her legs were buckled. On 08Mar2021, five days after first dose, the patient experienced nausea when she was in bed. It was reported that, the patient was still very tired since last dose and it had been over a month. Honestly thought the public needed to know more information about adverse side effects instead of describing it as flu. She had flu many times and the flu shot. That did not compare as to how this vaccine made her feel. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event fatigue - still fatigued beyond belief/ still very tired since last dose and it had been over a month was not resolved; whereas the events chills, headache, legs so weak when she got out of bed, legs buckled and nausea was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Fever 104.8 less than 12 hours after administering below immunization. Vomiting with cyanosis. EMS called, to ER.
Pfizer-BioNTech 5-11yo formulation administered to a person over the age of 12 years. This was the patient's first dose of the COVID vaccine series.
Left deltoid area red swollen, hot to touch, no fever. DTAP #4 administered. Child fine otherwise.
Left deltoid area red and hot to touch. Swelling, area measured about 115cm. width.
Shoulder Injury Related to Vaccine Administration  - vaccine was administered in shoulder instead of the correct location in  the deltoid muscle. This is causing severe shoulder pain and limited range of motion. My physician prescribed anti-inflammatory medications and physical therapy.  We do not know yet if there will be permanent damage.
Booster was given 6 days prior to 5 months per father's request. Father was advised that the recommendation is 6 months but he didn't want her to miss school again.
Dizziness, Headache, Myalgia, Fever, Diarrhea, Nausea Vomiting,  Chills, insomnia, Extreme Fatigue, Left sore arm  Narrative:
REVACCINATION WITH DIFFERENT COVID-19 VACCINE; CONFIRMED CLINICAL VACCINATION FAILURE; CONFIRMED COVID- 19 INFECTION; This spontaneous report received from a health care professional concerned a 24 year old female of an unspecified race. Initial information was processed along with the additional information received on 03-NOV-2022. The patient's height, and weight were not reported. The patient's concurrent conditions included: asthma, history of svt (Supraventricular tachycardia) penicillin allergy, and drug allergy (Amoxicillin, Augmentin, Tramadol, Hydrocodone, Codeine,). The patient received covid-19 vaccine ad26.cov2.s (Dose number in series: 1) (suspension for injection, route of admin not reported, batch number: 202A21A expiry: UNKNOWN) dose was not reported, 1 total administered on 06-APR-2021 for covid-19 prophylaxis. Age at time of vaccination 22 years old. No concomitant medications were reported. On 09-OCT-2021, the patient experienced covid-19 symptoms. On 11-OCT-2021 tested positive for covid-19 (Confirmed clinical vaccination failure) (Dose number in series 1). On 17-OCT-2021 tested negative for covid-19. On 19-OCT-2021, Covid symptoms rebound, Sore throat, headache, Congestion (Confirmed covid-19 infection) (Dose number in series 1). On 20-OCT-2021 and 21-OCT-2021 test was positive. The patient received Non-company suspect vaccine Tozinameran (Pfizer Biontech covid-19 vaccine) (Dose number in series 2) ( form of admin, route of admin, dose were not reported, batch number: EW0196 expiry: UNKNOWN, administered to left arm on 29-NOV-2021 for covid-19 prophylaxis and had Revaccination with different covid-19 vaccine (Dose number in series 2) It was unknown whether patient had any adverse events following covid-19 vaccine tozinameran (Pfizer biontech covid-19 vaccine) (Dose number in series 2). The patient was treated with Paxlovid (form of admin, route of admin were not reported, batch number: GE8833 and expiry: UNKNOWN) dose was not reported administered from 12-OCT-2022 to 15-OCT-2022 for treatment of covid-19. The action taken with covid-19 vaccine ad26.cov2.s, and tozinameran was not applicable and treatment with Paxlovid was discontinued. The patient was recovering from confirmed covid-19 infection, and the outcome of confirmed clinical vaccination failure and revaccination with different covid-19 vaccine was not reported. This report was serious (Other Medically Important Condition). This report was associated with a product quality complaint: 90000257779; Sender's Comments: V0: 20221104276- Confirmed clinical vaccination failure- The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event. Specifically: SPECIAL SITUATIONS. Therefore, this event is considered inconsistent with vaccine administration
muscle twitch in legs; left lip swollen; left nose swollen; This spontaneous case was reported by a consumer and describes the occurrence of MUSCLE TWITCHING (muscle twitch in legs), LIP SWELLING (left lip swollen) and NOSE DEFORMITY (left nose swollen) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced MUSCLE TWITCHING (muscle twitch in legs), LIP SWELLING (left lip swollen) and NOSE DEFORMITY (left nose swollen). On 24-Jan-2021, LIP SWELLING (left lip swollen) and NOSE DEFORMITY (left nose swollen) had resolved. At the time of the report, MUSCLE TWITCHING (muscle twitch in legs) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
6:15 - Patient give 0.5 ml Influenza vacc. IM. 9:00 - chest tightness & heaviness in throat. 10:15 - Patient reported to medical - pulse ox 99% - given 50 mL BENADRYL IM.
pharmacist administerd vaccine to 9 patients. It looks like the lots were expired; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (pharmacist administerd vaccine to 9 patients. It looks like the lots were expired) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7165B) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (pharmacist administerd vaccine to 9 patients. It looks like the lots were expired) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (pharmacist administerd vaccine to 9 patients. It looks like the lots were expired) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (pharmacist administerd vaccine to 9 patients. It looks like the lots were expired).    It was unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  No concomitant medications were provided.  There were no specific dates when administration occurred, but they had the lot number, and it was before 13 Jul 2023 and additional Lot numbers were 020H22A, 021H22A, 017H22A. The patients were fine.   Dosage text for suspect product was reported as unknown.  No treatment medication was provided.  This case contains information for the patient 9th out of 9 patients described by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-734387 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-734387:Master case
SICK; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (SICK) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In February 2021, the patient experienced ILLNESS (SICK). At the time of the report, ILLNESS (SICK) had not resolved.            Concomitant medication was not reported.  In Feb-2021 after second dose of vaccination patient got sick. Treatment details were not reported.  It was unknown if patient was enrolled in a COVID-19 vaccine Trial. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2021-620150 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 11-Apr-2022: Non-significant follow up received.
pt recv 2 doses of vax 8JUN95 & 18JUL(5 & 12OCT95 pt was tested for varicella antibody by latex agglutination & was non-immune;MD reported 9 pt;
Fever 99 degrees (starting 24 hours post injection lasting 2 days).  Severe lethargy (starting 6 hours post injection lasting 24 hours).  Moderate body aches 18 hours -> then severe body aches 6 hours -> then moderate body aches 10 hours.  Intermittent tingling and numbness in Right hand, wrist and thumb (injection was in Left bicep) starting 6 hours post injection.  Numbness in Right thumb and occasional tingling in right hand continues 1 week post injection.
Heart attack, pneumonia, bone marrow cancer, high protein in blood, amyloidosis, swollen liver, anemia
This spontaneous report as received form a pharmacist and pharmacy intern refers to 3 unspecified patients of unknown age and gender. The patients' pertinent medical history, drug reactions, allergies and concomitant medications were not reported. On 25-DEC-2015, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB injection, lot# K026666 with expiration date 22-OCT-2015 and lot# L019298 with expiration date 22-JUN-2017 (dose, route, lot # and expiration date were not reported). No adverse symptoms/effects were reported. This is one of the several reports from the same source. Additional information has been requested.
Left elbow and forearm pain after flu shot, began immediately after injection, gradually becoming numb off and on.  Injection site described as 3 fingers down from shoulder bone.
I  was about due to start menstruation around the time of dose 1. I have not menstruated since  late november/early december at this point in time. There is no possibility of this delay in menstruation being  pregnancy related. I have no  other known GYN issues.
cough; whole body ache; dizziness; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (cough), PAIN (whole body ache), DIZZINESS (dizziness) and VACCINATION SITE PAIN (sore arm) in a 36-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, the patient experienced COUGH (cough), PAIN (whole body ache), DIZZINESS (dizziness) and VACCINATION SITE PAIN (sore arm). On 15-Feb-2021, COUGH (cough), PAIN (whole body ache) and VACCINATION SITE PAIN (sore arm) had resolved. On 18-Feb-2021, DIZZINESS (dizziness) had resolved.
Within 48 hours of receiving the second vaccine I developed severe pain in my left chest wall and arm which was unrelieved with NSAIDS.  I also noted left axillary lymphadenopathy. I made an appointment with my pcp who ordered a CT scan
arm pain; barely lift the affected arm.; unable to turn in bed; This case was reported by a nurse via call center representative and described the occurrence of pain in arm in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on unknown date and did not have problems with it).   On 27th May 2019, the patient received the 2nd dose of Shingrix. In May 2019, less than a week after receiving Shingrix, the patient experienced injected limb mobility decreased and bedridden. On 27th May 2019, the patient experienced pain in arm. On an unknown date, the outcome of the pain in arm, injected limb mobility decreased and bedridden were unknown.   It was unknown if the reporter considered the pain in arm, injected limb mobility decreased and bedridden to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. Less than a day after receiving Shingrix, the patient developed severe pain in the arm and running the length of the arm, though there was no redness or evidence of a local reaction. Consequently, the patient could barely lift the affected arm. She was unable to turn in bed, lift or move the arm.
Arm pain at injection site, headache, generalized pain over entire body, chills.  Day two large welt developed over a larger area than injection site.  Continued through days 3 & 4.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of unknown age. Medical history, concurrent conditions, and concomitant medications were not provided. On or about 24-AUG-2015, the patient was inoculated at a pharmacy (by an unspecified health care professional) with ZOSTAVAX as recommended for routine adult health maintenance and for the prevention of shingles (dose, route of administration, site of administration and lot # were not provided). The vaccine did not prevent shingles as intended, and the male patient subsequently contracted a persistent strain of herpes zoster. On or about 13-MAY-2016, the male patient was treated (by an unspecified healthcare professional) at an Urgent care facility, for a persistent and severe vesicular rash, which was diagnosed as herpes zoster, or shingles. The patient has been prescribed VALTREX for management of his painful symptoms. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. The lawyer felt the events were related to ZOSTAVAX. Additional information has been requested.
A few days after vaccination, patient started experiencing swollen supra clavical lymph node.  Swelling fluctuates from not present to large and noticeable.   Patient had CT scan of area on 5/12/2021 which she reports was read as no masses and not of concern.  Follows up with primary care provider on 6/8/2021.
On 10/10/2008 I received a pneumonia shot at this Pharmacy + a flue shot. At 10:30 AM buy 3:30 PM I removed the bandage and noticed my arm was red hot & swollen. I called the clinic. The nurse said to keep using ice packs & Tylenol.The pneumonia paper said to notify the (VAERS)
Contracted COVID-19 from my wife who recently returned from an out of state trip. My symptoms began about 3 days after hers. Severe sore throat, some breathing stress and wheezing, headache, low grade fever of about 100.5, and some severe coughing. The fever started on Friday 7/1 and continued until Monday until 7/4. The sore throat continued to be severe until Wednesday 7/6. My labored breathing continued until 7/7, but my sore throat lessened then. I continue to have slight wheezing. The medications that I took were HALLS cough drops, 1000mg of vitamin C for about 10 days starting on 7/1. I also took some cough syrup, aspirin, ADVIL, and TYLENOL at different points to help with headache and fever. I took a home test but came up negative, however was presumed positive. Did email my primary care and they responded to treat with OTC medication based on symptoms, and would only prescribe medication if I had a confirmed lung infection.
Dizzy when ambulating to bathroom, fell, hit head, had subsequent seizure-like activity
Pt recv  1st & 2nd dose of vax in 1996; pt exp hair thinning for past 1 yr
My 13 year old son received his 2nd Pfizer vaccine yesterday Monday Jun 7th and about a half hour to an hour later he developed a runny nose. Today Tuesday June 8th, he still has the runny nose, his temp is now 99.5. I am concerned about the runny nose as this is not listed as a common side effect of the vaccine. I have a call out to his Pediatrician.
Received 5 immunizations on 3/27/01. Left thigh with erythema 8cm X 10cm diameter at injection site.
6mm red macular, papular lesion to left thigh. Mom stated that it came up day after shots were given.
Pt recvd vax & same evening exp visual disturbances (streaks), hyperventilation, sweating & nausea; next day exp inc fatigue, nausea, dizziness, aches, edema in hands, swelling of breasts, swelling of vulva; stress react, anxiety attack;
Chills, fever (102 F), back pain, wheezing, SOB, extreme fatigue, cough.
Several years, post vax, pt was diagnosed with multiple sclerosis. Pt stated that his symptoms started a few months, post vax. He sought unspecified medical attention. No further information is expected.
PFIZER COVID VACCINE #3 GIVEN 11/18/21, LOT #FF2593; pt came to hosp and was admitted on 4/24/22 with weakness, SOB, fever, cough, congestion, decrease in appetite; 4/25/22 positive COVID test; 80% O2 sat on RA; placed on O2 supplementation with improvement; CXR showed left lower lobe pneumonia; given ABX; pt passed away in the hospital the following day
Patient requested that the shot be administered in her gluteus maximus. She returned 1 week later complaining the injection site was red and hot to the touch. She said no fever was present. I asked her to get it checked out by a physician. She later told me that it was cellulitis.
High levels of liver function test; This case was reported by a pharmacist via call center representative and described the occurrence of liver function test increased in a 88-year-old male patient who received Herpes zoster (Shingrix) (batch number 99D9F, expiry date 14th April 2020) for prophylaxis.   On 26th April 2019, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. In May 2019, less than a month after receiving Shingrix, the patient experienced liver function test increased. On an unknown date, the outcome of the liver function test increased was unknown.   It was unknown if the reporter considered the liver function test increased to be related to Shingrix.  Additional details were provided as follows: The pharmacist stated that the patient received the 1st dose of Shingrix vaccine on right deltoid. About 1 week later patient had blood work done and the results showed high levels of liver function test. No further details were provided at time of reporting.
No additional adverse events were reported; The healthcare worker is reporting that a patient received improperly stored vaccine.; This spontaneous report was received from a health worker and refers to a 4-year-old male patient.  The patient's concurrent conditions included asthma. His medical history, drug allergies or reactions and concomitant therapies were not reported.  On 17-AUG-2023, the patient received a dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (recombinant human albumin (rHA)) 1 dose, lot #W000996 (which was confirmed to be a valid lot # for measles, mumps, rubella and varicella (oka-merck) virus vaccine live, (PROQUAD)), expiration date 08-JUL-2024 subcutaneously in left arm (strength not provided) as prophylaxis, that prior underwent a temperature excursion of 29 degrees Fahrenheit for 4 hours and 30 minutes due to a power outage (product storage error). No additional adverse events were reported.  This is one of several cases reported by the same reporter.
Red, hot, itchy lump several centimeters wide and deep at Shingrex injection site within 24 hours of injection. Still persists 7 days later without much reduction. Joint pain (back and other locations) and muscle soreness (buttocks, legs), mostly resolved after several days.
I have been amenorrheic since the birth of my child (March 2019,  this is my third child and I have previously remained amenorrheic until I completely finished nursing.  My toddler still nurses 2-4 times daily)  the day after my shot I had started menstration very suddenly and very heavily.  I was so surprised by the volume, I use a menstrual cup with a 1 ounce volume and over the course of six (a normal period for me is 3 ) days I measured 9 ounces of flow.  This period was sudden, twice as long and twice as heavy as usual.
Erythema, edema, itching at injection site BENADRYL prn.